One of the few conditions with an approved cannabis medicine, and an honest ceiling on what it does.
Approval rests on randomized trials in patients whose spasticity did not respond to standard treatment. A meaningful minority respond well, early-response designs show roughly a third reach the responder threshold.
Nabiximols MS trials, PubMed ↗Across MS trials, patient-reported spasticity and pain improvements are consistently larger than objective spasm measurements. Both numbers are real; they measure different things.
Subjective vs objective spasticity, PubMed ↗The large CUPID trial tested whether THC could slow disease progression and found no meaningful effect. Symptom relief, yes; modifying the disease, no, a distinction that matters enormously for treatment decisions.
CUPID progression trial, PubMed ↗Secondary trial outcomes and observational data suggest improvements in bladder urgency and sleep quality in MS patients using cannabinoids. Plausible and patient-valued, but these are secondary endpoints, not primary evidence.
Cannabinoids MS bladder sleep, PubMed ↗Cannabis is not an approved treatment for multiple sclerosis in most jurisdictions, and nothing here recommends using it. If multiple sclerosis affects your life, bring this research, literally, these sources, to a physician and decide together. Laws differ by country and state; check CannabisLaws.ai before anything else.
Is it legal where you live? Tell us your city to see the law status and minimum age.
Status for all 64 jurisdictions on CannabisLaws. Not legal advice.